- Home
- PIII vs LPCN Comparison
PIII vs LPCN Comparison
Compare PIII & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- LPCN
- Stock Information
- Founded
- PIII 2015
- LPCN 1997
- Country
- PIII United States
- LPCN United States
- Employees
- PIII N/A
- LPCN N/A
- Industry
- PIII Medical/Nursing Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- LPCN Health Care
- Exchange
- PIII Nasdaq
- LPCN Nasdaq
- Market Cap
- PIII 33.2M
- LPCN 36.8M
- IPO Year
- PIII N/A
- LPCN N/A
- Fundamental
- Price
- PIII $0.21
- LPCN $5.16
- Analyst Decision
- PIII Buy
- LPCN Strong Buy
- Analyst Count
- PIII 3
- LPCN 1
- Target Price
- PIII $2.38
- LPCN $10.00
- AVG Volume (30 Days)
- PIII 735.3K
- LPCN 26.5K
- Earning Date
- PIII 11-12-2024
- LPCN 11-07-2024
- Dividend Yield
- PIII N/A
- LPCN N/A
- EPS Growth
- PIII N/A
- LPCN N/A
- EPS
- PIII N/A
- LPCN N/A
- Revenue
- PIII $1,476,630,000.00
- LPCN $7,922,926.00
- Revenue This Year
- PIII $22.79
- LPCN N/A
- Revenue Next Year
- PIII $14.15
- LPCN N/A
- P/E Ratio
- PIII N/A
- LPCN N/A
- Revenue Growth
- PIII 25.38
- LPCN N/A
- 52 Week Low
- PIII $0.19
- LPCN $2.38
- 52 Week High
- PIII $1.78
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- PIII 30.66
- LPCN 49.88
- Support Level
- PIII $0.19
- LPCN $4.64
- Resistance Level
- PIII $0.25
- LPCN $5.40
- Average True Range (ATR)
- PIII 0.04
- LPCN 0.51
- MACD
- PIII -0.01
- LPCN -0.07
- Stochastic Oscillator
- PIII 11.91
- LPCN 34.48
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.